Novo Nordisk | NVO - Gross Profit On Sales


Novo Nordisk reported DKK64.01B in Gross Profit on Sales for its fiscal quarter ending in June of 2025.





Gross Profit On Sales Change Date
ANI Pharmaceuticals USD 124.18M 12.39M Dec/2025
Aurora Cannabis CAD 46.62M 14.33M Dec/2025
Bausch Health Companies USD 2B 67M Dec/2025
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Canopy Growth CAD 21.47M 434K Dec/2025
Corcept Therapeutics USD 162.02M 37.56M Mar/2026
Drreddys Laboratories INR 46.81B 10.24B Dec/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
GlaxoSmithKline GBP 5.75B 429M Mar/2026
Merck USD 10.85B 2.57B Dec/2025
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Novartis USD 10.07B 184M Mar/2026
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Pacira USD 126.64M 15.61M Mar/2026
Perrigo USD 325.5M 36.7M Mar/2026
Phibro Animal Health USD 133.5M 12.6M Dec/2025
Prestige Brands USD 157.37M 5.79M Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Supernus Pharmaceuticals USD 129.36M 34.68M Mar/2026
Zoetis USD 1.62B 20M Mar/2026